SOSV

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

ViAn Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop treatment aimed at replacing traditional invasive injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical testing, ViAn is poised to address significant unmet medical needs within the retinal disease sector, which represents a substantial market opportunity. In addition to its focus on ophthalmology, ViAn is also engaged in creating peptide drugs designed to inhibit angiogenesis, potentially benefiting patients suffering from cancer and other angiogenesis-dependent diseases. Through its innovative approaches, ViAn Therapeutics seeks to enhance patient outcomes and improve the overall quality of life for individuals affected by these conditions.

Laguna Bio is a biotechnology company focused on cancer treatment through its innovative drug discovery platform. Founded in 2022 and headquartered in Berkeley, California, the company specializes in selectively activating and expanding the innate immune system to combat solid tumors. By enhancing the response rate of bispecific antibody drugs, Laguna Bio aims to provide specific T cells that strengthen the immune system's ability to fight cancer, ultimately improving survival rates for patients facing this deadly disease.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

ZiO Health is a biotechnology company focused on enhancing patient outcomes through its innovative pocket-sized laboratory testing technology. The company has developed proprietary biosensor devices that utilize machine learning algorithms to provide real-time results tailored to individual patient profiles. These multi-functional electronic devices are designed for measuring, testing, and detecting the molecular composition of various chemical and biological substances, enabling users to assess the presence, absence, or quantity of specific target molecules. By delivering quality home diagnostics and personalized testing solutions, ZiO Health aims to empower individuals to optimize their health and prevent illness.

ViAn Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop treatment aimed at replacing traditional invasive injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical testing, ViAn is poised to address significant unmet medical needs within the retinal disease sector, which represents a substantial market opportunity. In addition to its focus on ophthalmology, ViAn is also engaged in creating peptide drugs designed to inhibit angiogenesis, potentially benefiting patients suffering from cancer and other angiogenesis-dependent diseases. Through its innovative approaches, ViAn Therapeutics seeks to enhance patient outcomes and improve the overall quality of life for individuals affected by these conditions.

FeetMe is a digital health company that specializes in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative footwear products equipped with connected insoles that analyze patients' mobility and posture in real time. By integrating pressure sensors and motion algorithms, FeetMe's technology provides valuable insights into gait patterns and movement disorders. This enables healthcare professionals to enhance patient care, monitor disease progression, and optimize treatment plans. FeetMe's focus on delivering relevant digital biomarkers supports clinical research and aims to improve the quality of life for individuals facing mobility challenges.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Lura Health is a pioneering company that has developed a non-invasive continuous health monitoring platform utilizing saliva as a diagnostic fluid. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company focuses on chronic disease management, targeting conditions such as heart disease, chronic kidney disease, diabetes, and tooth decay. Lura Health's innovative sensors are designed to be integrated into patient-friendly orthodontic devices, including removable retainers and fixed brackets. These sensors continuously monitor oral acidity and other analytes in saliva, automatically transmitting valuable health data to a mobile application. This approach empowers users to track key diagnostic metrics within their oral environment, facilitating improved personal health management and potentially enhancing clinical outcomes.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

ViAn Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop treatment aimed at replacing traditional invasive injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical testing, ViAn is poised to address significant unmet medical needs within the retinal disease sector, which represents a substantial market opportunity. In addition to its focus on ophthalmology, ViAn is also engaged in creating peptide drugs designed to inhibit angiogenesis, potentially benefiting patients suffering from cancer and other angiogenesis-dependent diseases. Through its innovative approaches, ViAn Therapeutics seeks to enhance patient outcomes and improve the overall quality of life for individuals affected by these conditions.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Kolibri is a biotechnology company focused on revolutionizing large-scale cell culture to enhance accessibility and affordability in cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that employs advanced techniques in acoustics and biology, enabling its bioreactors to achieve a 90-fold increase in cell yield while significantly reducing production costs by up to 50 times. Kolibri's innovative bioreactors are designed to facilitate the efficient growth of cells at scale, thereby supporting partners in drug development and providing critical solutions for unlocking patient access to gene therapies and next-generation vaccines. Through its technological advancements, Kolibri aims to address key challenges in the bioproduction of biologics.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

BiomeSense, Inc. is a Chicago-based company founded in 2018 that focuses on developing a comprehensive platform for microbiome data collection and analysis. Its primary innovation is the GutLab, a "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology is integrated with the MetaBiome time-series analytics platform, offering a seamless end-to-end solution that enables real-time tracking of microbiome changes and their correlation with clinical outcomes. By generating and analyzing extensive longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, providing healthcare professionals with a high-resolution microbiome database. This resource supports the development of advanced microbiome-based therapeutics and consumer products, ultimately enhancing precision medicine and improving health outcomes.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Laguna Bio is a biotechnology company focused on cancer treatment through its innovative drug discovery platform. Founded in 2022 and headquartered in Berkeley, California, the company specializes in selectively activating and expanding the innate immune system to combat solid tumors. By enhancing the response rate of bispecific antibody drugs, Laguna Bio aims to provide specific T cells that strengthen the immune system's ability to fight cancer, ultimately improving survival rates for patients facing this deadly disease.

Filtricine, Inc., founded in 2017 and based in Santa Clara, California, is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. The company's approach involves targeted nutrient deprivation, which identifies and exploits metabolic vulnerabilities specific to cancer cells. By depleting nutrients critical to cancer growth without using traditional drugs, Filtricine aims to provide effective treatments that minimize harm to healthy cells.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Chronos DX is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics within the healthcare sector. The company is known for its innovative bioassay technology, which is designed for diagnostics, drug screening, and development. Chronos DX focuses on creating high-performance, low-cost, and scalable technology capable of detecting a variety of biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This technology provides medical professionals with a platform for in-line and in vivo monitoring of biomarkers, enhancing the capabilities of diagnostics and drug development in medical practice.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, founded in 2016. It operates a proprietary drug discovery platform that utilizes synthetic biology to expand the druggable proteome, focusing on therapeutic applications in oncology and rare diseases. The platform employs empirical intracellular selection to identify and design compounds that can modulate protein interactions, either disrupting specific protein-protein interactions or facilitating the targeted degradation of proteins through the recruitment of E3 ubiquitin ligases. SyntheX's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that evade chemotherapy through homologous recombination. The company identifies drug targets by analyzing clinical, evolutionary, phenotypic, and structural data, and it maintains both internal oncology projects and collaborative discovery initiatives.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

Aksense is a biotechnology company focused on developing affordable and portable nucleic acid-based diagnostic panels for the rapid and accurate detection of pathogens. It has created the first portable rapid infection diagnostic biosensor designed to enhance the quality of care in healthcare settings. Aksense aims to improve antibiotic prescribing practices and public health outcomes by enabling early detection and treatment of infections. Its technology facilitates faster recovery for patients through cost-effective molecular testing, ultimately reducing the spread of infections and improving overall patient outcomes.

Conan MedTech, founded in 2020 and based in Ithaca, New York, is focused on developing rapid point-of-care diagnostic tests for concussions. The company's innovative healthcare system aims to transform the diagnosis of mild traumatic brain injuries, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions on the sidelines during games. By providing real-time concussion detection and efficient medical assistance, Conan MedTech enhances the ability of medical professionals to assess athletes swiftly and improve their quality of life through timely interventions.

Conan MedTech, founded in 2020 and based in Ithaca, New York, is focused on developing rapid point-of-care diagnostic tests for concussions. The company's innovative healthcare system aims to transform the diagnosis of mild traumatic brain injuries, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions on the sidelines during games. By providing real-time concussion detection and efficient medical assistance, Conan MedTech enhances the ability of medical professionals to assess athletes swiftly and improve their quality of life through timely interventions.

FeetMe is a digital health company that specializes in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative footwear products equipped with connected insoles that analyze patients' mobility and posture in real time. By integrating pressure sensors and motion algorithms, FeetMe's technology provides valuable insights into gait patterns and movement disorders. This enables healthcare professionals to enhance patient care, monitor disease progression, and optimize treatment plans. FeetMe's focus on delivering relevant digital biomarkers supports clinical research and aims to improve the quality of life for individuals facing mobility challenges.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally invented at Cornell University, Inso Biosciences enhances the efficiency of processing cellular material. The company's platform is designed to facilitate genomic analysis, including applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. By enabling healthcare and biotechnology companies to effectively separate and isolate cellular components, Inso Biosciences aims to transform the landscape of biological sample preparation.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device that facilitates blood type analysis and the detection of various infectious diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. The company's portable platform operates independently of electricity and does not require additional laboratory infrastructure, making it accessible for use in diverse settings. Criam's device allows for rapid and accurate blood testing, which enhances clinical decision-making by providing timely health information. The technology is designed to be scalable, with one reader capable of performing multiple tests using specialized cartridges and computer vision algorithms. This innovation aims to improve the efficiency and reliability of blood testing services, ultimately enhancing patient care.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Indee Labs is focused on developing innovative hardware for gene delivery, specifically designed to facilitate the efficient development and scalable manufacture of gene-modified cell therapies, such as chimeric antigen receptor T cells. The company has created a non-viral intracellular delivery system that integrates with standard reagents, optimizing the recovery of viable modified cells with minimal disruption. Utilizing microfluidic vortex shedding technology, Indee Labs' system enables the gentle delivery of macromolecules, nucleic acids, and gene-editing complexes to various cell types. The company collaborates with the Australian National Fabrication Facility for its technology development and has established lab space at Bonneville Labs in Berkeley while expanding its operations with a new office in Sydney. Indee Labs has been associated with various prestigious incubators and programs, including NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

Filtricine, Inc., founded in 2017 and based in Santa Clara, California, is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. The company's approach involves targeted nutrient deprivation, which identifies and exploits metabolic vulnerabilities specific to cancer cells. By depleting nutrients critical to cancer growth without using traditional drugs, Filtricine aims to provide effective treatments that minimize harm to healthy cells.

Filtricine, Inc., founded in 2017 and based in Santa Clara, California, is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. The company's approach involves targeted nutrient deprivation, which identifies and exploits metabolic vulnerabilities specific to cancer cells. By depleting nutrients critical to cancer growth without using traditional drugs, Filtricine aims to provide effective treatments that minimize harm to healthy cells.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

BiomeSense, Inc. is a Chicago-based company founded in 2018 that focuses on developing a comprehensive platform for microbiome data collection and analysis. Its primary innovation is the GutLab, a "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology is integrated with the MetaBiome time-series analytics platform, offering a seamless end-to-end solution that enables real-time tracking of microbiome changes and their correlation with clinical outcomes. By generating and analyzing extensive longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, providing healthcare professionals with a high-resolution microbiome database. This resource supports the development of advanced microbiome-based therapeutics and consumer products, ultimately enhancing precision medicine and improving health outcomes.

Kolibri is a biotechnology company focused on revolutionizing large-scale cell culture to enhance accessibility and affordability in cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that employs advanced techniques in acoustics and biology, enabling its bioreactors to achieve a 90-fold increase in cell yield while significantly reducing production costs by up to 50 times. Kolibri's innovative bioreactors are designed to facilitate the efficient growth of cells at scale, thereby supporting partners in drug development and providing critical solutions for unlocking patient access to gene therapies and next-generation vaccines. Through its technological advancements, Kolibri aims to address key challenges in the bioproduction of biologics.

Dalton Bioanalytics is a company that specializes in analytical technology aimed at transforming blood analysis and enhancing preventative healthcare. Founded in 2019 and based in Los Angeles, California, Dalton Bioanalytics addresses the inefficiencies and high costs associated with traditional laboratory testing. Its innovative technology digitizes the biochemical composition of blood, allowing for a comprehensive array of health insights derived from a single assay. This capability enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules. By deciphering the biochemical signatures in blood, Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

BiomeSense, Inc. is a Chicago-based company founded in 2018 that focuses on developing a comprehensive platform for microbiome data collection and analysis. Its primary innovation is the GutLab, a "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology is integrated with the MetaBiome time-series analytics platform, offering a seamless end-to-end solution that enables real-time tracking of microbiome changes and their correlation with clinical outcomes. By generating and analyzing extensive longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, providing healthcare professionals with a high-resolution microbiome database. This resource supports the development of advanced microbiome-based therapeutics and consumer products, ultimately enhancing precision medicine and improving health outcomes.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

ANA Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutic solutions for the treatment of coronavirus, specifically COVID-19. Founded in 2020 and based in Foster City, California, the company is advancing a proprietary formulation of niclosamide, marketed under the name ANA001. This drug is delivered in capsule form and is currently undergoing human clinical trials. The objective of ANA Therapeutics is to provide effective treatment options for medical practitioners to help patients affected by the coronavirus pandemic, thereby aiming to contribute to the global response to this public health crisis.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

Arthronica Ltd is a technology company based in London, United Kingdom, focused on developing an artificial intelligence-based platform for patient monitoring and rehabilitation, specifically targeting chronic rheumatic conditions such as arthritis. Founded in 2018, Arthronica's solutions incorporate advanced features such as skeletal tracking, visual strength assessment, image analysis, and video analysis. The company aims to provide medical practitioners with tools to accurately monitor and predict disease activities, thereby enhancing patient care and treatment outcomes. Currently, Arthronica is engaged in clinical trials in both the United Kingdom and the United States, and it has participated in the Entrepreneur First program, which supports the growth of technology startups.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

Dalton Bioanalytics is a company that specializes in analytical technology aimed at transforming blood analysis and enhancing preventative healthcare. Founded in 2019 and based in Los Angeles, California, Dalton Bioanalytics addresses the inefficiencies and high costs associated with traditional laboratory testing. Its innovative technology digitizes the biochemical composition of blood, allowing for a comprehensive array of health insights derived from a single assay. This capability enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules. By deciphering the biochemical signatures in blood, Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine.